截至6月30日，呈和科技股东户数4274.00，较上期增加30.07%；人均流通股44061股，较上期增加 6.99%。2025年1月-6月，呈和科技实现营业收入4.71亿元，同比增长13.77%；归母净利润1.47亿元，同 比增长15.33%。 分红方面，呈和科技A股上市后累计派现3.93亿元。近三年，累计派现3.03亿元。 10月9日，呈和科技跌0.68%，成交额1.57亿元。两融数据显示，当日呈和科技获融资买入额2157.96万 元，融资偿还2720.69万元，融资净买入-562.73万元。截至10月9日，呈和科技融资融券余额合计2.77亿 元。 融资方面，呈和科技当日融资买入2157.96万元。当前融资余额2.77亿元，占流通市值的3.90%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，呈和科技10月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，呈和科技股份有限公司位于广东省广州市白云区北太路1633号广州民营科技园科强路2号， 成立日期2002年1月31日，上市 ...

Investment Rating - The report maintains a "Buy-B" rating for the company [5] Core Views - The company achieved steady revenue growth in the first half of 2025, with total revenue of 471 million yuan, up 13.77% year-on-year, and a net profit of 147 million yuan, up 15.33% year-on-year [1][2] - The company is actively seizing market opportunities, accelerating product innovation, and expanding its application downstream, which has led to increased market share and steady performance growth [2] - The modified plastics industry has significant growth potential, and the nucleating agent sector is at a critical stage of domestic substitution, with the company positioned to lead in high-performance nucleating agents [3][4] Financial Performance - In the first half of 2025, the nucleating agent segment generated 297 million yuan in revenue, while synthetic talc, NDO composite additives, and antioxidants contributed 63 million yuan, 31 million yuan, and 38 million yuan, respectively [2] - The company's overseas revenue reached 120 million yuan, indicating strong international market performance [2] - The gross margin for the first half of 2025 was 45.79%, an increase of 0.7 percentage points year-on-year, while the expense ratio was 10.46%, up 1.63 percentage points year-on-year [2] Industry Outlook - From 2019 to 2023, China's modified plastics production increased from 19.55 million tons to 29.75 million tons, with a compound annual growth rate of 11.07%, indicating a robust growth trajectory for the industry [3] - The high-end modified plastics market in China still relies heavily on imports, and the industry is currently at a pivotal point for domestic substitution [3] Investment Projections - The projected net profits for 2025, 2026, and 2027 are 277 million yuan, 336 million yuan, and 380 million yuan, respectively, with corresponding price-to-earnings ratios of 23.2, 19.2, and 17 times [5][9]

Investment Rating - The investment rating for the company is "Buy" and it is maintained [10] Core Views - The company achieved a revenue of 471 million yuan in the first half of 2025, representing a year-on-year increase of 13.8%, and a net profit attributable to shareholders of 147 million yuan, up 15.3% year-on-year [2][7] - In Q2 alone, the company generated a revenue of 251 million yuan, which is a 12.7% increase year-on-year and a 14.0% increase quarter-on-quarter [2][7] - The company's main products, nucleating agents and synthetic hydrotalcite, are key raw materials for producing high-performance resins, and the domestic substitution is accelerating amid global trade policy fluctuations [13] - The company has completed its IPO project and fully utilized its Nansha plant, enhancing its production capacity significantly [13] - The overseas revenue reached 120 million yuan in the first half of 2025, marking a substantial growth of 70.1% year-on-year, indicating a strong international strategy [13] - The company aims to become a "definer" of comprehensive solutions in high polymer materials, enhancing customer satisfaction and loyalty through customized services [13] - The company is a leader in the domestic nucleating agent and synthetic hydrotalcite market, with potential for continued market share growth [13] Financial Summary - The company forecasts net profits of 297 million yuan, 348 million yuan, and 401 million yuan for the years 2025, 2026, and 2027 respectively [13] - The total revenue is projected to reach 1.058 billion yuan in 2025, with a gross profit margin of 44% [19] - The company’s net profit margin is expected to be around 28.1% in 2025 [19]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][19] Core Views - The company achieved steady growth in net profit in the first half of 2025, with a revenue of 471 million yuan, representing a year-on-year increase of 13.77%, and a net profit of 147 million yuan, up 15.33% year-on-year. The growth is attributed to the increased domestic market penetration and localization of polymer material additives [1][9][10] - The company is the largest domestic seller of nucleating agents and is positioned to benefit from the increasing domestic substitution rate due to rising international trade tensions. The nucleating agent market is expected to exceed 1 billion USD globally by 2025 [2][18] - The company plans to continue seeking strategic acquisitions to enhance its competitive strength and promote high-quality development, despite the recent termination of a planned acquisition of a leading ITO target material company [2][18] Financial Performance Summary - In the first half of 2025, the nucleating agent segment generated 297 million yuan in revenue, a 17.29% increase year-on-year, accounting for 62.97% of total revenue with a gross margin of 56.05% [10] - The company’s revenue forecast for 2025-2027 is adjusted to 301 million, 350 million, and 402 million yuan respectively, with diluted EPS of 1.60, 1.86, and 2.13 yuan [3][19] - The company’s overall sales gross margin was 45.79%, with a net profit margin of 31.26% in the first half of 2025, reflecting a year-on-year improvement [9][10] Business Segmentation - The nucleating agent segment is the largest contributor to revenue, followed by synthetic hydrotalcite and antioxidant segments, with significant growth observed in the antioxidant segment, which saw a 129% year-on-year increase in revenue [10] - International revenue reached 120 million yuan, a 70.08% increase year-on-year, indicating strong overseas market performance [10] Market Outlook - The company is well-positioned to capitalize on the growing demand for nucleating agents and synthetic hydrotalcite, with a focus on expanding both domestic and international markets [2][18] - The anticipated increase in the domestic substitution rate for nucleating agents is expected to accelerate due to international trade risks, providing further growth opportunities for the company [2][18]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [10][12]. Core Insights - The company is a leader in the domestic nucleating agent and synthetic hydrotalcite market, with strong competitiveness in antioxidant and NDO composite additives. The penetration rate of domestic nucleating agents and synthetic hydrotalcite remains low, indicating potential for continued growth in the company's main business. Projected net profits for 2025, 2026, and 2027 are estimated at 360 million, 439 million, and 518 million yuan respectively [3][10]. Company Overview - The company has been deeply engaged in the polymer material additive sector for over 20 years, establishing itself as a leader in nucleating agents and synthetic hydrotalcite. It has successfully developed and marketed nucleating agent products, gaining recognition from major downstream manufacturers and expanding into both domestic and international markets [6][22]. Nucleating Agents - The demand for nucleating agents is growing significantly, with domestic demand increasing from 4,600 tons in 2016 to 9,520 tons in 2022, reflecting a compound annual growth rate of 12.9%. In 2023, China's nucleating agent demand accounted for approximately 27% of the global market, second only to North America [7][61]. - The company benefits from a competitive edge as domestic nucleating agent prices are generally 1/3 to 1/2 lower than imported products, driven by lower production costs and reduced logistics expenses [7]. Synthetic Hydrotalcite - Synthetic hydrotalcite is primarily used as a heat stabilizer in PVC production and as a halogen absorber in polyolefin resin production. The demand for synthetic hydrotalcite has maintained rapid growth, with domestic leading companies achieving technological breakthroughs and accelerating import substitution [8][24]. Antioxidants - In 2023, the company entered the antioxidant sector through acquisitions, enhancing its product line. The antioxidant products are primarily specialized hindered phenolic antioxidants, widely used in various applications including nylon and polyurethane [9][10]. Financial Analysis - The company has shown steady revenue growth, with significant contributions from its core products, particularly nucleating agents. From 2018 to 2024, the sales volume of nucleating agents increased from 2,349 tons to 9,728 tons, a growth rate exceeding 314% [38][43]. - The company maintains a high gross margin, consistently above 40%, and has optimized its expense structure, enhancing its market competitiveness and profitability [45][52]. Investment Recommendations - Given the company's strong market position, growth potential in nucleating agents and synthetic hydrotalcite, and the recent expansion into antioxidants, the report recommends a "Buy" rating for investors looking for opportunities in the polymer additive sector [10][12].

Core Insights - The company reported a revenue of 882 million RMB for 2024, representing a year-on-year increase of 10%, and a net profit attributable to shareholders of 250 million RMB, up 11% year-on-year [1] - In Q1 2025, the company achieved a revenue of 220 million RMB, reflecting a 15% increase year-on-year, with a net profit of 71 million RMB, up 16% year-on-year [1] Revenue Breakdown - For FY 2024, the revenue from nucleating agents, synthetic hydrotalcite, NDO composite additives, and antioxidants was 510 million, 120 million, 60 million, and 70 million RMB respectively, with year-on-year changes of +24%, -1%, +28%, and -20% [2] - The gross profit margins for these products were 56%, 47%, 25%, and 15%, with year-on-year changes of -1, +3, -1, and -7 percentage points respectively [2] - The sales volume of nucleating agents reached 9,728 tons, marking a 32% increase year-on-year [2] Market Outlook - The national polypropylene production in 2024 is projected to be 34.72 million tons, a 7% increase year-on-year, with total capacity expected to reach 43.39 million tons, up 9% year-on-year [2] - The demand for nucleating agents is anticipated to grow due to the increasing application of polypropylene materials in emerging fields such as new energy and environmental protection [2] Strategic Acquisition - The company is planning to acquire at least 51% of YINGRI Technology, a leading manufacturer of ITO targets, with an estimated valuation of 1.8 billion RMB for 100% of the shares [3] - YINGRI Technology is recognized as a "national-level specialized and innovative small giant enterprise" and has achieved technical parity with foreign counterparts in large-size ITO target manufacturing [3] - The acquisition is expected to create synergies in customer resource sharing and brand influence, facilitating the company's entry into the display industry [3] Profit Forecast - The projected net profit attributable to shareholders for 2025-2027 is estimated to be 330 million, 440 million, and 540 million RMB respectively [4]